These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Shinkaruk S; Bayle M; Laïn G; Déléris G Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules. Zachary I IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611 [TBL] [Abstract][Full Text] [Related]
7. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Nicosia RF Am J Pathol; 1998 Jul; 153(1):11-6. PubMed ID: 9665459 [No Abstract] [Full Text] [Related]
8. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Brown LF; Detmar M; Claffey K; Nagy JA; Feng D; Dvorak AM; Dvorak HF EXS; 1997; 79():233-69. PubMed ID: 9002222 [TBL] [Abstract][Full Text] [Related]
11. Translational Research: the Role of VEGF in Tumor Angiogenesis. Proceedings of a symposium. Washington, DC, USA. November 16, 1999. Oncologist; 2000; 5 Suppl 1():1-57. PubMed ID: 10804083 [No Abstract] [Full Text] [Related]
12. Regulation of angiogenesis via vascular endothelial growth factor receptors. Veikkola T; Karkkainen M; Claesson-Welsh L; Alitalo K Cancer Res; 2000 Jan; 60(2):203-12. PubMed ID: 10667560 [No Abstract] [Full Text] [Related]
13. Regulators of angiogenesis as targets for anti-angiogenic tumor therapy. Breier G; Heidenreich R; Gaumann A; Groot M; Licht A; Nicolaus A; Schmitz J; Reichmann E; Plate KH; Vajkoczy P Ann Hematol; 2002; 81 Suppl 2():S71-2. PubMed ID: 12611084 [No Abstract] [Full Text] [Related]
14. VEGFs, receptors and angiogenesis. Veikkola T; Alitalo K Semin Cancer Biol; 1999 Jun; 9(3):211-20. PubMed ID: 10343072 [TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and angiogenic mediators in haematological malignancies. Mangi MH; Newland AC Br J Haematol; 2000 Oct; 111(1):43-51. PubMed ID: 11091181 [No Abstract] [Full Text] [Related]
17. Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now? Leenders WP Int J Exp Pathol; 1998 Dec; 79(6):339-46. PubMed ID: 10319015 [TBL] [Abstract][Full Text] [Related]